Can Exercise Training Reduce the Frequency and Severity of Hot Flushes Associated With Breast Cancer Treatment?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Helen Jones, Professor
- Phone Number: 0151 904 6270
- Email: H.Jones1@ljmu.ac.uk
Study Contact Backup
- Name: Aine Brislane, MSc
- Phone Number: 0151 904 6278
- Email: a.brislane@2016.ljmu.ac.uk
Study Locations
-
-
Merseyside
-
Liverpool, Merseyside, United Kingdom, L33AF
- Research Institute for Sport and Exercise Sciences (RISES)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to provide written informed consent
- Pre-menopausal, Peri-menopausal or post-menopausal
- >4 hot flushes per day
- Female
- Treated with tamoxifen or aromatase inhibitor
Exclusion Criteria:
- Uncontrolled or severe hypertension (blood pressure > 160/100 mm Hg)
- Any previous injury preventing exercise
- Type 1 or 2 diabetes
- Anti-depressants
- Currently undergoing chemotherapy or radiotherapy
- Current smoker
- Cannot readily read and understand English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Exercise Intervention
Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms.
Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
|
A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Thermoregulation
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Participants will wear a tube-lined suit that allows manipulation of skin temperature by heating the water passed through the tubes.
Core temperature will be increased by 1 degree (monitored using a temperature pill) with sweat rate and skin temperature recordings taken at 5minute intervals across 1 hour of heating.
Thermoregulation will be compared during this hour to that of the post-exercise intervention re-test.
|
Change from pre- to post- 16 week exercise intervention
|
|
Change in Skin Blood Flow
Time Frame: Change from pre- to post- 16 week exercise intervention
|
The change in skin blood flow will be measured using laser Doppler probes at the forearm.
|
Change from pre- to post- 16 week exercise intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Cerebral Blood Flow
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Change in cerebral blood flow will be assessed using transcranial Doppler ultrasound to measure brain blood flow.
|
Change from pre- to post- 16 week exercise intervention
|
|
Change in Vascular Function
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Vascular function will be measured via endothelial-dependent flow mediated dilation of the brachial artery and reported as a percentage change.
|
Change from pre- to post- 16 week exercise intervention
|
|
Change in Vascular Structure
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Vascular structure will be measured at the carotid artery using ultrasound imaging to clearly visualise the artery.
The image will be adjusted so artery wall thickness can be clearly seen with a 30 second recording taken at 3 different angles.
The average of the three angles will be calculated with results reported as change in millimetres.
|
Change from pre- to post- 16 week exercise intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Helen Jones, Professor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 16/NW/0166
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
NCT05020860RecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer
-
NCT02580448CompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast
-
NCT00003199CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer
-
NCT01372579UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer
-
NCT01881048CompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer
-
NCT01151449TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer
-
NCT01632332CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer
-
NCT02315196Active, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer
-
NCT01222377TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
NCT07214883RecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer Awareness
Clinical Trials on Exercise Intervention
-
NCT05436600RecruitingMobility Impairment | Asymptomatic Carotid Stenosis (50-69%)
-
NCT01344928UnknownType 2 Diabetes Mellitus | Healthy Volunteers
-
NCT07229963Not yet recruitingSubstrate Oxidation | Postprandial Metabolism | Exercise Physiology | Cardiovascular Risk Markers
-
NCT06571253Completed
-
NCT01047410CompletedMetabolic Syndrome | Kidney Transplant | Post-transplant Weight Gain
-
NCT03058887CompletedQuality of Life | Systemic Sclerosis | Raynaud's Phenomenon
-
NCT03648762Completed